ACADIA Pharmaceuticals Inc. (ACAD)

18.63
1.10 6.28
NASDAQ : Health Technology
Prev Close 17.53
Open 17.40
Day Low/High 17.40 / 18.83
52 Wk Low/High 12.77 / 32.99
Volume 1.48M
Avg Volume 2.78M
Exchange NASDAQ
Shares Outstanding 125.08M
Market Cap 2.23B
EPS -2.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

ACADIA Pharmaceuticals Announces Positive Top-line Results From Phase 2 CLARITY Trial Of Pimavanserin For Adjunctive Treatment In Patients With Major Depressive Disorder (MDD)

ACADIA Pharmaceuticals Announces Positive Top-line Results From Phase 2 CLARITY Trial Of Pimavanserin For Adjunctive Treatment In Patients With Major Depressive Disorder (MDD)

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced positive top-line results from CLARITY, a randomized, double-blind, placebo-controlled, multi-center, sequential parallel comparison design (SPCD) study in major depressive disorder (MDD).

ACADIA Pharmaceuticals Announces Executive Leadership Change

ACADIA Pharmaceuticals Announces Executive Leadership Change

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) today announced that Todd S.

Interesting ACAD Put And Call Options For June 2019

Interesting ACAD Put And Call Options For June 2019

Investors in Acadia Pharmaceuticals Inc saw new options become available this week, for the June 2019 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 239 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Dropbox, XPO Logistics, Ford Motor: 'Mad Money' Lightning Round

Dropbox, XPO Logistics, Ford Motor: 'Mad Money' Lightning Round

Jim Cramer weighs in on Dropbox, XPO Logistics, Ford Motor Co., Acadia Pharmaceuticals, Avalara, and more.

ACADIA Pharmaceuticals To Announce Third Quarter 2018 Financial Results On November 6, 2018

ACADIA Pharmaceuticals To Announce Third Quarter 2018 Financial Results On November 6, 2018

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will report its...

ACADIA Pharmaceuticals Announces Executive Appointments To Lead Medical Affairs And Science

ACADIA Pharmaceuticals Announces Executive Appointments To Lead Medical Affairs And Science

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced two executive...

ACADIA Pharmaceuticals To Present At The 2018 Cantor Global Healthcare Conference On October 2, 2018

ACADIA Pharmaceuticals To Present At The 2018 Cantor Global Healthcare Conference On October 2, 2018

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at...

8 Stocks Poised to Change Direction

8 Stocks Poised to Change Direction

These names are showing technical characteristics of either bullish or bearish reversal patterns.

FDA Issues Statement Reaffirming The Positive Benefit-Risk Profile Of NUPLAZID® (pimavanserin) For Patients With Hallucinations And Delusions Associated With Parkinson's Disease Psychosis

FDA Issues Statement Reaffirming The Positive Benefit-Risk Profile Of NUPLAZID® (pimavanserin) For Patients With Hallucinations And Delusions Associated With Parkinson's Disease Psychosis

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) today announced that the FDA has completed a postmarketing review and issued a clear statement reaffirming the positive benefit-risk profile of NUPLAZID (pimavanserin) for patients with Parkinson's disease...

Interesting ACAD Put And Call Options For January 2021

Interesting ACAD Put And Call Options For January 2021

Investors in Acadia Pharmaceuticals Inc saw new options become available this week, for the January 2021 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 850 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

ACADIA PHARMACEUTICALS 24 HOUR DEADLINE ALERT: Approximately 24 Hours Remain; ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Deadline In Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. - ACAD

ACADIA PHARMACEUTICALS 24 HOUR DEADLINE ALERT: Approximately 24 Hours Remain; ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Deadline In Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. - ACAD

ClaimsFiler, a FREE shareholder information service, reminds investors that they have only until September 17, 2018 to file lead plaintiff applications in a securities class action lawsuit against ACADIA Pharmaceuticals Inc.

Investors: The Law Offices Of Howard G. Smith Reminds Investors Of Lead Plaintiff Deadline In The Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. (ACAD)

Investors: The Law Offices Of Howard G. Smith Reminds Investors Of Lead Plaintiff Deadline In The Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. (ACAD)

Law Offices of Howard G. Smith reminds investors of the September 17, 2018 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased ACADIA Pharmaceuticals Inc.

Analyses Of Pimavanserin Studies Evaluating Treatment In Alzheimer's Disease Psychosis And Parkinson's Disease Psychosis Published In The Journal Of Prevention Of Alzheimer's Disease Suggest Potential For Treating Dementia-Related Psychosis

Analyses Of Pimavanserin Studies Evaluating Treatment In Alzheimer's Disease Psychosis And Parkinson's Disease Psychosis Published In The Journal Of Prevention Of Alzheimer's Disease Suggest Potential For Treating Dementia-Related Psychosis

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) announced today publication of additional data from a Phase 2 single center, double-blind, placebo-controlled study to examine the safety and efficacy of pimavanserin for the treatment of psychosis in Alzheimer's...

ACADIA Pharmaceuticals To Present At The Morgan Stanley 16th Annual Global Healthcare Conference On September 13, 2018

ACADIA Pharmaceuticals To Present At The Morgan Stanley 16th Annual Global Healthcare Conference On September 13, 2018

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at...

ACAD NOTICE: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against ACADIA Pharmaceuticals Inc.; Important Sept. 17 Deadline - ACAD

ACAD NOTICE: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against ACADIA Pharmaceuticals Inc.; Important Sept. 17 Deadline - ACAD

NEW YORK, Sept. 1, 2018 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of ACADIA Pharmaceuticals Inc.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses On Their Investment In ACADIA Pharmaceuticals Inc. Of Class Action Lawsuit And Upcoming Deadline - ACAD

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses On Their Investment In ACADIA Pharmaceuticals Inc. Of Class Action Lawsuit And Upcoming Deadline - ACAD

NEW YORK, Aug. 29, 2018 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against ACADIA Pharmaceuticals Inc.

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Acadia Pharmaceuticals, Inc. To Contact The Firm

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Acadia Pharmaceuticals, Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Acadia Pharmaceuticals, Inc.

ACADIA PHARMACEUTICALS SHAREHOLDER ALERT: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. - ACAD

ACADIA PHARMACEUTICALS SHAREHOLDER ALERT: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. - ACAD

ClaimsFiler, a FREE shareholder information service, reminds investors that they have until September 17, 2018 to file lead plaintiff applications in a securities class action lawsuit against ACADIA Pharmaceuticals Inc.

SHAREHOLDER ALERT: WeissLaw LLP Investigates Acadia Pharmaceuticals, Inc.

SHAREHOLDER ALERT: WeissLaw LLP Investigates Acadia Pharmaceuticals, Inc.

NEW YORK, Aug. 24, 2018 /PRNewswire/ -- WeissLaw LLP, a national class action, shareholder rights law firm with offices in New York, Los Angeles, and Atlanta, announces an investigation of Acadia Pharmaceuticals, Inc.

First Week Of October 19th Options Trading For Acadia Pharmaceuticals (ACAD)

First Week Of October 19th Options Trading For Acadia Pharmaceuticals (ACAD)

Investors in Acadia Pharmaceuticals Inc saw new options begin trading this week, for the October 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ACAD options chain for the new October 19th contracts and identified one put and one call contract of particular interest.

ACADIA PHARMACEUTICALS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. - ACAD

ACADIA PHARMACEUTICALS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. - ACAD

NEW ORLEANS, Aug. 17, 2018 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until September 17, 2018 to file lead plaintiff applications in a securities class action lawsuit against ACADIA...

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In ACADIA Pharmaceuticals, Inc. To Contact The Firm

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In ACADIA Pharmaceuticals, Inc. To Contact The Firm

NEW YORK, Aug. 17, 2018 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in ACADIA Pharmaceuticals, Inc.

INVESTOR REMINDER: Kessler Topaz Meltzer & Check, LLP Announces Deadline In Securities Fraud Class Action Lawsuit Filed Against ACADIA Pharmaceuticals Inc.

INVESTOR REMINDER: Kessler Topaz Meltzer & Check, LLP Announces Deadline In Securities Fraud Class Action Lawsuit Filed Against ACADIA Pharmaceuticals Inc.

The law firm of Kessler Topaz Meltzer & Check, LLP reminds ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Reports Second Quarter 2018 Financial Results

ACADIA Pharmaceuticals Reports Second Quarter 2018 Financial Results

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced its financial...

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Acadia Pharmaceuticals, Inc. To Contact The Firm

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Acadia Pharmaceuticals, Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Acadia Pharmaceuticals, Inc.

ACADIA Pharmaceuticals And Neuren Pharmaceuticals Announce Exclusive License Agreement For The North American Development And Commercialization Of Trofinetide In Rett Syndrome

ACADIA Pharmaceuticals And Neuren Pharmaceuticals Announce Exclusive License Agreement For The North American Development And Commercialization Of Trofinetide In Rett Syndrome

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) and Neuren Pharmaceuticals Limited (ASX: NEU) announced today that they have entered into an exclusive North American License Agreement for the development and commercialization of trofinetide for Rett syndrome...